BRPI0915605A2 - Vacina de leishmania usando imunógeno salivar de mosca tipo borrachudo - Google Patents

Vacina de leishmania usando imunógeno salivar de mosca tipo borrachudo

Info

Publication number
BRPI0915605A2
BRPI0915605A2 BRPI0915605A BRPI0915605A2 BR PI0915605 A2 BRPI0915605 A2 BR PI0915605A2 BR PI0915605 A BRPI0915605 A BR PI0915605A BR PI0915605 A2 BRPI0915605 A2 BR PI0915605A2
Authority
BR
Brazil
Prior art keywords
borrachudo
salivar
immunogen
type fly
leishmania vaccine
Prior art date
Application number
Other languages
English (en)
Inventor
Laurent Bernard Fischer
Jesus G Valenzuela
Original Assignee
The Government Of The Us Secretary Of The Dept Of Healt & Human Services
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The Us Secretary Of The Dept Of Healt & Human Services, Merial Inc filed Critical The Government Of The Us Secretary Of The Dept Of Healt & Human Services
Publication of BRPI0915605A2 publication Critical patent/BRPI0915605A2/pt
Publication of BRPI0915605B1 publication Critical patent/BRPI0915605B1/pt
Publication of BRPI0915605B8 publication Critical patent/BRPI0915605B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0915605-4 2008-05-08 2009-05-06 Vacina de leishmania usando imunógeno salivar de mosca tipo borrachudo BRPI0915605B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5163508P 2008-05-08 2008-05-08
US61/051,635 2008-05-08
US10134508P 2008-09-30 2008-09-30
US61/101,345 2008-09-30
PCT/US2009/042980 WO2009137577A2 (en) 2008-05-08 2009-05-06 Leishmania vaccine using sand fly salivary immunogen

Publications (3)

Publication Number Publication Date
BRPI0915605A2 true BRPI0915605A2 (pt) 2016-02-02
BRPI0915605B1 BRPI0915605B1 (pt) 2021-08-24
BRPI0915605B8 BRPI0915605B8 (pt) 2021-09-08

Family

ID=41110966

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915605-4 BRPI0915605B8 (pt) 2008-05-08 2009-05-06 Vacina de leishmania usando imunógeno salivar de mosca tipo borrachudo

Country Status (10)

Country Link
US (2) US8603808B2 (pt)
EP (2) EP2283035B1 (pt)
CN (2) CN102066411A (pt)
AR (1) AR071696A1 (pt)
BR (1) BRPI0915605B8 (pt)
ES (1) ES2760004T3 (pt)
IL (1) IL209107A (pt)
MA (1) MA32376B1 (pt)
MX (2) MX348137B (pt)
WO (1) WO2009137577A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX348137B (es) * 2008-05-08 2017-05-29 Merial Ltd Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
NZ706288A (en) 2012-08-30 2016-06-24 Merial Inc Expression of chimeric ksac protein and method of producing soluble proteins by high pressure
US20160194660A1 (en) * 2012-12-21 2016-07-07 Merck Sharp & Dohme Corp. Expression vectors for recombinant protein production in mammalian cells
CA2966191A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
AR111842A1 (es) 2017-06-02 2019-08-21 Amgen Inc Antagonistas de péptido pac1
CN113337542A (zh) * 2021-06-10 2021-09-03 山西大学 高效表达利什曼原虫pepck的人复制缺陷型重组腺病毒载体

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
GB2197321B (en) 1986-09-12 1990-10-03 Genentech Inc Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5529780A (en) 1994-03-30 1996-06-25 Virogenetics Corporation Nucleotide and amino acid sequences of canine herpesvirus gB and gC
CA2214029A1 (en) 1995-04-25 1996-10-31 Magda Marquet Single-vial formulations of dna/lipid complexes
EP0803573A1 (en) 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression construct with cytokines for multivalent vaccines
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
TWI224107B (en) 1998-10-22 2004-11-21 Pfizer Prod Inc Novel proteins from actinobacillus pleuropneumoniae
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
SK287400B6 (sk) 1999-09-25 2010-08-09 University Of Iowa Research Foundation Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
EP1203819A3 (en) 2000-10-06 2002-08-07 Transgene S.A. Anti-inflammatory vectors
BR0210539A (pt) * 2001-06-19 2005-04-26 Us Gov Health & Human Serv Processos de seleção e uso de vacinas de vetor antiartrópode
FR2829498B1 (fr) 2001-09-11 2003-11-28 Merial Sas Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
WO2003062374A2 (en) 2001-11-09 2003-07-31 Entremed, Inc. Synthetic genes for malarial proteins and methods of use
WO2004024027A2 (en) 2002-06-07 2004-03-25 University Of Florida Endodontic files made using bulk metallic glasses
MXPA05004714A (es) * 2002-10-29 2006-03-17 Us Gov Health & Human Serv Polipeptidos de lutzomyia longipalpis y metodos de uso.
MXPA06004025A (es) * 2003-10-24 2006-06-28 Mologen Ag Farmaco para el tratamiento de infecciones por leishmanias.
CA2570156C (en) 2004-06-04 2014-09-30 Merial Limited Needle-free administration of felv vaccines
US7512883B2 (en) * 2004-06-30 2009-03-31 Microsoft Corporation Portable solution for automatic camera management
CA2540736A1 (en) * 2005-04-08 2006-10-08 Institut Pasteur Polypeptides of leishmania major and polynucleotides encoding same and vaccinal, therapeutical and diagnostic applications thereof
BRPI0719078A2 (pt) * 2006-11-21 2013-12-03 Merial Ltd Vacina contra leishmania canina
US20100278752A1 (en) * 2007-08-02 2010-11-04 Rhode Island Board Of Governors For Higher Education Methods for Detection and Prevention of Tick Infestation and Pathogen Transmission
MX348137B (es) * 2008-05-08 2017-05-29 Merial Ltd Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
US8425919B2 (en) * 2008-05-21 2013-04-23 Infectious Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
US8410258B2 (en) * 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
WO2010078469A2 (en) * 2008-12-31 2010-07-08 The Usa As Represented By The Secretary, Department Of Health And Human Services Sand fly salivary proteins as novel factor xa inhibitors and methods of use
WO2010078466A2 (en) * 2008-12-31 2010-07-08 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Sand fly salivary proteins with anti-complement activity and methods of their use
US9226958B2 (en) * 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
EP2640186B1 (en) * 2010-11-18 2018-02-28 Merial, Inc. Leishmania canine challenge model by sand fly bites
WO2013011184A2 (es) * 2011-07-21 2013-01-24 Consejo Superior De Investigaciones Científicas (Csic) Molécula quimerica util en inmunoterapia frente a la leishmaniosis, que comprende un fragmento de la proteina pfr1 de leishmania infantum con epitopes especificos inmunodominantes
NZ700470A (en) * 2012-03-20 2016-04-29 Merial Inc Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof

Also Published As

Publication number Publication date
EP2899203B1 (en) 2019-07-10
EP2283035B1 (en) 2015-07-29
BRPI0915605B8 (pt) 2021-09-08
US9228002B2 (en) 2016-01-05
MA32376B1 (fr) 2011-06-01
WO2009137577A3 (en) 2010-03-25
US20140294875A1 (en) 2014-10-02
US8603808B2 (en) 2013-12-10
MX2010012069A (es) 2010-12-14
EP2283035A2 (en) 2011-02-16
AR071696A1 (es) 2010-07-07
ES2760004T3 (es) 2020-05-12
CN103768588A (zh) 2014-05-07
IL209107A0 (en) 2011-01-31
EP2899203A3 (en) 2015-08-05
US20090324649A1 (en) 2009-12-31
HK1150616A1 (zh) 2012-01-06
CN102066411A (zh) 2011-05-18
BRPI0915605B1 (pt) 2021-08-24
WO2009137577A2 (en) 2009-11-12
IL209107A (en) 2017-08-31
MX348137B (es) 2017-05-29
EP2899203A2 (en) 2015-07-29

Similar Documents

Publication Publication Date Title
IL269427B (en) Vaccine nanotechnology
DK2114993T3 (da) Vaccine
BRPI0911604A2 (pt) vacinas de polipeptídeo de flagelina
ATE450271T1 (de) Impfstoff
BR112012030950A2 (pt) formulações de vacina
BRPI1010909A2 (pt) "inseticida arilpirrolinas"
BRPI0917205A2 (pt) vacina polivalente
HRP20181347T1 (hr) Formulacije dvoslojne tablete
NO20084470L (no) Tradlos fjernstyring for sementhode
BRPI1014856A2 (pt) "elementos de tração"
BR112012004593A2 (pt) "método"
BRPI0920630A2 (pt) vacina combinada com pertússis acelular
DK2326651T3 (da) Buprenorphinanaloger
BRPI0914533A2 (pt) "métodos"
DK2402032T3 (da) Immunogen sammensætning
BRPI1012606A2 (pt) exposição multivalente de adjuvante
BRPI0906946A2 (pt) Vacinas baseadas em baculovírus
EP2515938A4 (en) IMMUNOGENIC COMPOSITIONS
DK2609931T3 (da) Immunogen sammensætning
SMT202100150T1 (it) Formulazioni migliorate
DK2422810T3 (da) Influenzavaccine
BRPI0915605A2 (pt) Vacina de leishmania usando imunógeno salivar de mosca tipo borrachudo
BRPI0921578A2 (pt) vacinas unitemporais
EP2498815A4 (en) VACCINE COMPOSITION
NO20100811A (no) Subenhetsvaksine for akvakutur

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DAS PRIORIDADES US 61/051,635 DE 08/05/2008 E US 61/101,345 DE 30/09/2008 REIVINDICADAS NO PCT/US2009/042980, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT SER DISTINTO DAQUELE QUE DEPOSITOU A PRIORIDADE REIVINDICADA E NAO APRESENTOU DOCUMENTO COMPROBATORIO DE CESSAO, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, ITEM 27 DO ATO NORMATIVO 128/97 E NO ART. 28 DA RESOLUCAO INPI-PR 77/2013.

B12F Other appeals [chapter 12.6 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS

B25A Requested transfer of rights approved

Owner name: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/05/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2642 DE 24/08/2021 QUANTO AO TITULAR.

B25A Requested transfer of rights approved

Owner name: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH AND HUMAN SERVICES (US) ; BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.